Pyrroloquinoline quinone ameliorates PM2 .5‐induced pulmonary fibrosis through targeting epithelial–mesenchymal transition
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18299 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Chia-Chia Chao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Therapy, Fu Jen Catholic University, New Taipei, Taiwan. Hauptthemen laut MEDLINE: Pulmonary Fibrosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Fu Jen Catholic University, Chi Mei Medical Center.
Abstract (Originalsprache)
Pulmonary fibrosis is a lung disorder affecting the lungs that involves the overexpressed extracellular matrix, scarring and stiffening of tissue. The repair of lung tissue after injury relies heavily on Type II alveolar epithelial cells (AEII), and repeated damage to these cells is a crucial factor in the development of pulmonary fibrosis. Studies have demonstrated that chronic exposure to PM2.5, a form of air pollution, leads to an increase in the incidence and severity of pulmonary fibrosis by stimulation of epithelial–mesenchymal transition (EMT) in lung epithelial cells. Pyrroloquinoline quinone (PQQ) is a bioactive compound found naturally that exhibits potent anti‐inflammatory and anti‐oxidative properties. The mechanism by which PQQ prevents pulmonary fibrosis caused by exposure to PM2.5 through EMT has not been thoroughly discussed until now. In the current study, we discovered that PQQ successfully prevented PM2.5‐induced pulmonary fibrosis by targeting EMT. The results indicated that PQQ was able to inhibit the expression of type I collagen, a well‐known fibrosis marker, in AEII cells subjected to long‐term PM2.5 exposure. We also found the alterations of cellular structure and EMT marker expression in AEII cells with PM2.5 incubation, which were reduced by PQQ treatment. Furthermore, prolonged exposure to PM2.5 considerably reduced cell migratory ability, but PQQ treatment helped in reducing it. In vivo animal experiments indicated that PQQ could reduce EMT markers and enhance pulmonary function. Overall, these results imply that PQQ might be useful in clinical settings to prevent pulmonary fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Therapy, Fu Jen Catholic University, New Taipei, Taiwan.
- Division of Hematology-Oncology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
- Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Nursing, Chung Hwa University of Medical Technology, Tainan, Taiwan.
- Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.
- Division of Physical Medicine and Rehabilitation, Fu Jen Catholic University Hospital, Taipei, Taiwan, ROC.
ORCID-Profile: Po-Chun Chen
Förderung
- National Science and Technology Council
- Fu Jen Catholic University
- Chi Mei Medical Center
- Shin Kong Wu Ho-Su Memorial Hospital
Zitieren
APA
Chao, C. C., Hsiao, S. Y., Kao, W. C., Chiou, P. C., Huang, C. C., Wang, M. T., & Chen, P. C. (2024). Pyrroloquinoline quinone ameliorates PM2 .5‐induced pulmonary fibrosis through targeting epithelial–mesenchymal transition. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18299
Vancouver
Chao CC, Hsiao SY, Kao WC, Chiou PC, Huang CC, Wang MT, et al. Pyrroloquinoline quinone ameliorates PM2 .5‐induced pulmonary fibrosis through targeting epithelial–mesenchymal transition. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18299
BibTeX
@article{Chao2024,
author = {Chao, Chia-Chia and Hsiao, Sheng-Yen and Kao, Wan-Chen and Chiou, Pei-Chen and Huang, Chieh-Chen and Wang, Mei-Ting and Chen, Po-Chun},
title = {Pyrroloquinoline quinone ameliorates PM2 .5‐induced pulmonary fibrosis through targeting epithelial–mesenchymal transition},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18299}
}
EUVIMED